# Frank Griesinger
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/frank-griesinger/
## Facts
| Field | Value |
| --- | --- |
| Citations | 14,799 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 56 |
| i10-index | 174 |
| Last Known Institution | Pius Hospital Oldenburg |
| OpenAlex ID | https://openalex.org/A5052962511 |
| ORCID iD | 0000-0002-6822-5498 |
| Works | 604 |
## Researcher papers
- [Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease](https://scholariq.org/papers/standardized-rt-pcr-analysis-of-fusion-gene-transcripts-from-chromosome/)
- [Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial](https://scholariq.org/papers/high-dose-methotrexate-with-or-without-whole-brain-radiotherapy-for-primary-cns/)
- [Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/neratinib-after-trastuzumab-based-adjuvant-therapy-in-her2-positive-breast/)
- [Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-alk-inhibitor-naive-advanced-alk-positive-nsclc/)
- [Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-advanced-alk-inhibitor-naive-alk-positive-non/)
- [Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer](https://scholariq.org/papers/chemoradiotherapy-plus-induction-or-consolidation-chemotherapy-as-total/)
- [Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study](https://scholariq.org/papers/alectinib-versus-chemotherapy-in-crizotinib-pretreated-anaplastic-lymphoma/)
- [Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML](https://scholariq.org/papers/screening-for-mll-tandem-duplication-in-387-unselected-patients-with-aml/)
- [Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy](https://scholariq.org/papers/small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-dll3/)
- [1336P Small cell transformation in EGFR-mutated non-small cell lung cancer (EGFR+ NSCLC): Efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with platinum-based chemotherapy](https://scholariq.org/papers/1336p-small-cell-transformation-in-egfr-mutated-non-small-cell-lung-cancer-egfr/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
## Researcher university
- [Pius Hospital Oldenburg](https://scholariq.org/institutions/pius-hospital-oldenburg/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.